CD8A and neoplasm: TIGIT ligands on the surface of tumor-infiltrating CD8+T cells or Tregs can bind to PVR receptors of tumor cells or dendritic cells, promote the production of anti-inflammatory cytokines such as IL-10 and inhibit the immune response.